Which of the following reflects a potential weakness in the FDA review of new GMOs of a kind that is different than the FDA review of novel, conventional food sources?
1) FDA may not have sufficient scientific capacity to review or verify the information submitted to the agency.
2) FDA does not conduct a review of the environmental impact of GMOS.
3) There may be unknown allergens in GMO-derived foods that are not revealed without long term studies.
4) We don't know what we don't know about GMOs.
5) Unknown toxins in GMOs may create unexpected risk.